Subscribe or Manage Preferences

Sarilumab Efficacy Maintained or Improved in Previously Treated Patients with RA

VBCR - December 2017, Vol 6, No 5 - ACR 2017 Conference Correspondent, Rheumatoid Arthritis

 

The ASCERTAIN trial was a randomized, double-blind, parallel-group, 3-arm safety and tolerability study that evaluated sarilumab (150 mg or 200 mg every 2 weeks [q2w]) versus tocilizu­mab in patients with rheumatoid arthritis (RA) and inadequate response to, or intolerance of, tumor necrosis factor inhibitors receiving background conventional synthetic disease-modifying antirheumatic drugs. The multicenter, extension EXTEND study assessed the long-term safety of sarilumab. It enrolled patients from 5 trials—ASCERTAIN, MOBILITY, TARGET, ONE, and ACT11575. This post hoc analysis examined efficacy and safety outcomes from patients who completed the ASCERTAIN trial and switched to subcutaneous sarilumab 200 mg q2w.

In this analysis, clinical end points assessed were Disease Activity Score 28–C-reactive protein (DAS28-CRP), Clinical Disease Activity Index (CDAI), and 20%/50%/70% improvement in American College of Rheumatology response criteria (ACR20/ACR50/ACR70). Definitions used as cutoffs for remission and low disease activity (LDA) were DAS28-CRP <2.6 and <3.2, and CDAI ≤2.8 and ≤10.0, respectively. Nonresponders were patients who had not achieved these threshold levels of remission and LDA at enrollment in EXTEND.

A total of 175 patients completed the ASCERTAIN trial; of these, 168 continued into the EXTEND trial: 93 from the tocilizumab group, 37 from the sarilumab 150-mg group, and 38 from the sarilumab 200-mg group.

Improvements in DAS28-CRP and CDAI occurred in patients who were nonresponders on enrollment in EXTEND, defined by DAS28-CRP ≥3.2 and CDAI >10. Importantly, higher proportions of nonresponders switching from tocilizumab or sarilumab 150 mg q2w achieved DAS28-CRP or CDAI remission or LDA at week 24 compared with those who continued to receive sarilumab 200 mg q2w. Of these, the greatest increases were noted in patients who initially received tocilizumab, suggesting that switching tocilizumab nonresponders to sarilumab may have favorable efficacy outcomes. For ACR20/ACR50/ACR70 nonresponders on entry into EXTEND, similar proportions of patients from each of the subgroups achieved an ACR response.

The authors concluded that the efficacy of sarilumab was maintained (sar­ilumab 200 mg q2w) or improved (sar­ilumab 150 mg q2w or tocilizumab) in patients who switched or continued into the open-label EXTEND trial after completion of the ASCERTAIN trial.

Source: Emery P, van Hoogstraten H, Jayawardena S, et al. Efficacy of sarilumab in patients with rheumatoid arthritis who previously received sarilumab or tocilizumab. Arthritis Rheumatol. 2017;69(suppl 10). Abstract 2468.

Related Items
Web-Based Smartphone Application Useful for Monitoring Changes in RA Disease Activity
Sophie Granger
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in Rheumatoid Arthritis
Upadacitinib Is Effective in Patients with Active RA with Inadequate Response to Conventional Synthetic DMARDs
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Efficacy and Safety of Switching from Adalimumab to Sarilumab
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
No Increased Cardiovascular Risk in Patients with RA Who Newly Initiated Tocilizumab versus Abatacept
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Cost per Effectively Treated Patient with Sarilumab for Active, Moderate-to-Severe RA
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Sustained Response Following Discontinuation of MTX in Subcutaneous Tocilizumab-Treated Patients with RA
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Suboptimal EHR Reporting of Clinical Measures in Patients with RA Receiving a Biologic or Targeted Synthetic DMARD
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Tocilizumab Monotherapy as Effective as TNF Inhibitors plus MTX in Patients with RA
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Sarilumab plus DMARDs Lower HbA1c in Diabetic and Nondiabetic Patients with RA
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Both Tofacitinib and Baricitinib in Combination with MTX Are Efficacious in Patients with RA
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Last modified: January 15, 2018
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology